Ann: Opthea Announces Completion of Drug Substance Campaign, page-47

I got a little greedy range trading another stock that bounced off its effective capital raise lows missing the rally to ASX200 inclusion. I will not make the same mistake in OPT. ASX200 inclusion during 2025 me thinks.

OPT has seen its lows IMO. The ASX300 removal in 2022 was the beginning of a well trodden decline (if we ignore the silly 2020-21 COVID/RBA cash give away period). ASX300 re-inclusion might mark the watershed of a sustained ascent as OPT gains favour again with the funds who so readily dropped it.

The last capital raise a painful one for existing shareholders, but also a buy opportunity already for those who could afford it at $0.40. I picked a load up in $0.30's on the secondary market - investors never learn and oversell these stocks on frustrated emotions rather than the potential commercial application they saw when they first bought, well outlined in this release.

GLTAH